Company news

Ironwood Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

December 11, 2023

Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

November 8, 2023

Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call

October 25, 2023

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

October 22, 2023

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

October 15, 2023

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

October 4, 2023

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

August 7, 2023

Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call

July 24, 2023

Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares

June 28, 2023

Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio

June 15, 2023

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

June 11, 2023

Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

May 21, 2023

Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference

May 8, 2023

Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

May 7, 2023

Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance

May 3, 2023

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

April 23, 2023

Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call

April 19, 2023

Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences

February 26, 2023

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

February 15, 2023

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

February 12, 2023

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call

February 1, 2023

Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance

January 8, 2023

Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 21, 2022

Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

November 2, 2022

Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

October 19, 2022

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

September 5, 2022

Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

August 31, 2022

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

August 3, 2022

Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call

July 20, 2022

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022

May 24, 2022

Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

May 8, 2022

Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

May 4, 2022

Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call

April 20, 2022

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

March 1, 2022

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021

February 16, 2022

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call

February 2, 2022

Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance

January 9, 2022

Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

November 30, 2021

Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update

November 3, 2021

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.

November 3, 2021

More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021

October 24, 2021

Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call

October 20, 2021

Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences

September 1, 2021

Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label

August 25, 2021

Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance

August 4, 2021

Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer

August 2, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 53 decks. Every deck is listed under its year.